California State Teachers Retirement System Decreases Position in Halozyme Therapeutics, Inc. (HALO)

California State Teachers Retirement System cut its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 9.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 193,466 shares of the biopharmaceutical company’s stock after selling 21,272 shares during the quarter. California State Teachers Retirement System owned approximately 0.14% of Halozyme Therapeutics worth $2,480,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Creative Planning lifted its stake in Halozyme Therapeutics by 1.2% in the 2nd quarter. Creative Planning now owns 114,667 shares of the biopharmaceutical company’s stock valued at $1,470,000 after buying an additional 1,383 shares in the last quarter. Chicago Equity Partners LLC lifted its stake in Halozyme Therapeutics by 85.5% in the 2nd quarter. Chicago Equity Partners LLC now owns 315,440 shares of the biopharmaceutical company’s stock valued at $4,044,000 after buying an additional 145,410 shares in the last quarter. Vanguard Group Inc. lifted its stake in Halozyme Therapeutics by 9.5% in the 2nd quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock valued at $123,010,000 after buying an additional 831,654 shares in the last quarter. BlackRock Inc. lifted its stake in Halozyme Therapeutics by 7,292.8% in the 1st quarter. BlackRock Inc. now owns 11,062,842 shares of the biopharmaceutical company’s stock valued at $143,374,000 after buying an additional 10,913,199 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in Halozyme Therapeutics by 7.7% in the 2nd quarter. Northern Trust Corp now owns 1,492,747 shares of the biopharmaceutical company’s stock valued at $19,138,000 after buying an additional 107,333 shares in the last quarter. 85.24% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Halozyme Therapeutics, Inc. (HALO) opened at $18.18 on Friday. The company has a quick ratio of 3.94, a current ratio of 3.46 and a debt-to-equity ratio of 2.01. Halozyme Therapeutics, Inc. has a 1-year low of $9.68 and a 1-year high of $19.37.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the Zacks’ consensus estimate of $0.06 by ($0.04). The business had revenue of $63.73 million during the quarter, compared to analyst estimates of $58.95 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The firm’s revenue was up 100.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.23) EPS. equities analysts forecast that Halozyme Therapeutics, Inc. will post 0.09 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/12/california-state-teachers-retirement-system-decreases-position-in-halozyme-therapeutics-inc-halo.html.

A number of brokerages recently weighed in on HALO. Canaccord Genuity raised their price target on shares of Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday. BMO Capital Markets raised their price target on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the company a “market perform” rating in a research note on Wednesday. Piper Jaffray Companies raised their price target on shares of Halozyme Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, October 16th. Zacks Investment Research lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 6th. Finally, Deutsche Bank AG raised their price target on shares of Halozyme Therapeutics to $20.00 and gave the company a “buy” rating in a research note on Friday, September 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $17.75.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply